Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RNA:DNA ratios in human tumors

L Kravetz de Srulijes, E Israeli, D Barzilai

    Journal of the National Cancer Institute
    |March 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    The ratio of ribonucleic acid to deoxyribonucleic acid (RNA:DNA) differs significantly between benign and malignant human tumors. This finding holds diagnostic value for various cancer types, including breast, thyroid, and Hodgkin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease.

    Human genetics·2018
    Same author

    Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

    Clinical and experimental immunology·2015
    Same author

    [IMAJ--medical research in Israel 2014].

    Harefuah·2015
    Same author

    [Spread of Chikungunya virus in the Americas 2013-2014].

    Harefuah·2014
    Same author

    [The Lancet crosses all boundaries].

    Harefuah·2014
    Same author

    Lancets unethical behavior.

    The Israel Medical Association journal : IMAJ·2014

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biochemistry

    Background:

    • The RNA:DNA ratio is a key indicator of cellular metabolic activity.
    • Distinguishing between benign and malignant tumors is crucial for effective treatment.
    • Previous research has suggested potential differences in nucleic acid content between tumor types.

    Purpose of the Study:

    • To quantitatively assess the RNA:DNA ratio in benign versus malignant human tumors.
    • To determine if the RNA:DNA ratio can serve as a diagnostic marker for malignancy.
    • To explore the diagnostic value of RNA:DNA ratios across different tumor types.

    Main Methods:

    • Quantitative analysis of RNA and DNA content in tumor samples.
    • Calculation of the RNA:DNA ratio for each sample.

    Related Experiment Videos

  • Statistical analysis (Student's t-test) to compare ratios between benign and malignant groups.
  • Inclusion of breast, thyroid, and Hodgkin's disease (spleen) tumor cohorts.

    • Main Results:

    • A statistically significant difference in RNA:DNA ratios was observed between malignant and benign tumors in all studied groups.
    • Malignant breast tumors showed a significant difference compared to benign breast tumors (t=2.22, P<0.05).
    • Hodgkin's disease in the spleen exhibited a significant difference compared to controls (t=2.39, P<0.02).
    • Malignant thyroid tumors demonstrated a significant difference compared to benign thyroid tumors (t=4.23, P<0.01).

    Conclusions:

    • The RNA:DNA ratio is a significant differentiating factor between benign and malignant human tumors.
    • This quantitative marker shows promise as a diagnostic tool for various cancers.
    • Further discussion on the diagnostic utility and implications of RNA:DNA ratio differences is warranted.